Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Jul 19;2006(3):CD006115.
doi: 10.1002/14651858.CD006115.

Azapirones for generalized anxiety disorder

C A Chessick  1 , M H Allen, Me Thase, A B C Batista Miralha da Cunha, F F K Kapczinski, M S M L de Lima, J J S S dos Santos Souza
Affiliations
Review

Azapirones for generalized anxiety disorder

C A Chessick et al. Cochrane Database Syst Rev. .

Abstract

Background: Azapirones are a group of drugs that work at the 5-HT1A receptor and are used to treat patients suffering from generalized anxiety disorder (GAD). However, several studies have shown conflicting results. Whether azapirones are useful as first line treatment in general anxiety disorders still needs to be answered.

Objectives: To assess the efficacy and the acceptability of azapirones for the treatment of GAD.

Search strategy: Initially the Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register (CCDANCTR) and The Cochrane Central Register of Controlled Trials (CENTRAL) were searched, incorporating results of group searches of MEDLINE (1966 to June 2005), EMBASE (1980 to June 2005), CINAHL (1982 to June 2005), PsycLIT (1974 to June 2005), PSYNDEX (1977 to June 2005), and LILACS (1982 to June 2005). Subsequently the revised Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (CCDANCTR-Studies and CCDANCTR-References) were searched on 21-10-2005. Reference lists of relevant papers and major text books of anxiety disorder were examined. Authors, other experts in the field and pharmaceutical companies were contacted for knowledge of suitable trials, published or unpublished. Specialist journals concerning azapirones were handsearched.

Selection criteria: Randomized controlled trials of azapirones, including buspirone versus placebo and/or other medication and/or psychological treatment, were included. Participants were males and females of all ages with a diagnosis of generalized anxiety disorder.

Data collection and analysis: Data were extracted from the original reports independently by CC, MA and MT. The main outcomes studied were related to the objectives stated above. Data were analysed for generalized anxiety disorder versus placebo, versus other medication and versus psychological treatment separately. Data were analysed using Review Manager Version 4.2.7.

Main results: Thirty six trials were included in the review, reporting on 5908 participants randomly allocated to azapirones and/or placebo, benzodiazepines, antidepressants, psychotherapy or kava kava. Azapirones, including buspirone, were superior to placebo in treating GAD. The calculated number needed to treat for azapirones using the Clinical Global Impression scale was 4.4 (95% confidence interval (CI) 2.16 to 15.4). Azapirones may be less effective than benzodiazepines and we were unable to conclude if azapirones were superior to antidepressants, kava kava or psychotherapy. Azapirones appeared to be well tolerated. Fewer participants stopped taking benzodiazepines compared to azapirones. The length of studies ranged from four to nine weeks, with one study lasting 14 weeks.

Authors' conclusions: Azapirones appeared to be useful in the treatment of GAD, particularly for those participants who had not been on a benzodiazepine. Azapirones may not be superior to benzodiazepines and do not appear as acceptable as benzodiazepines. Side effects appeared mild and non serious in the azapirone treated group. Longer term studies are needed to show that azapirones are effective in treating GAD, which is a chronic long-term illness.

PubMed Disclaimer

Conflict of interest statement

None

Figures

1.1
1.1. Analysis
Comparison 1 Azapirones vs placebo, Outcome 1 HAM‐A score.
1.2
1.2. Analysis
Comparison 1 Azapirones vs placebo, Outcome 2 CGI much or very much improved.
1.3
1.3. Analysis
Comparison 1 Azapirones vs placebo, Outcome 3 Number of people who drop out.
1.4
1.4. Analysis
Comparison 1 Azapirones vs placebo, Outcome 4 Specific side effects.
2.1
2.1. Analysis
Comparison 2 Buspirone vs placebo, Outcome 1 HAM‐A score.
2.2
2.2. Analysis
Comparison 2 Buspirone vs placebo, Outcome 2 CGI much or very much improved.
2.3
2.3. Analysis
Comparison 2 Buspirone vs placebo, Outcome 3 Number of people who drop out.
2.4
2.4. Analysis
Comparison 2 Buspirone vs placebo, Outcome 4 Specific side effects.
3.1
3.1. Analysis
Comparison 3 Azapirone vs benzodiazepine, Outcome 1 HAM‐A score.
3.2
3.2. Analysis
Comparison 3 Azapirone vs benzodiazepine, Outcome 2 HAM‐A score, ipsapirone vs diazepam.
3.4
3.4. Analysis
Comparison 3 Azapirone vs benzodiazepine, Outcome 4 Number of people who drop out.
3.5
3.5. Analysis
Comparison 3 Azapirone vs benzodiazepine, Outcome 5 Specific side effects.
4.1
4.1. Analysis
Comparison 4 Buspirone vs benzodiazepine, Outcome 1 HAM‐A score, buspirone vs diazepam.
4.2
4.2. Analysis
Comparison 4 Buspirone vs benzodiazepine, Outcome 2 HAM‐A score, buspirone vs lorazepam.
4.3
4.3. Analysis
Comparison 4 Buspirone vs benzodiazepine, Outcome 3 HAM‐A score, buspirone vs alprazolam.
4.4
4.4. Analysis
Comparison 4 Buspirone vs benzodiazepine, Outcome 4 Number of people who drop out.
4.5
4.5. Analysis
Comparison 4 Buspirone vs benzodiazepine, Outcome 5 Specific side effects, buspirone.
5.1
5.1. Analysis
Comparison 5 Buspirone vs Venlafaxine XR, Outcome 1 CGI.
5.2
5.2. Analysis
Comparison 5 Buspirone vs Venlafaxine XR, Outcome 2 Number of people who drop out.
5.3
5.3. Analysis
Comparison 5 Buspirone vs Venlafaxine XR, Outcome 3 Specific side effects, Buspirone vs Venlafaxine XR 75 mg.
6.1
6.1. Analysis
Comparison 6 Buspirone vs Kava‐Kava, Outcome 1 CGI much or very much improved.
6.2
6.2. Analysis
Comparison 6 Buspirone vs Kava‐Kava, Outcome 2 Number of people who drop out.
6.3
6.3. Analysis
Comparison 6 Buspirone vs Kava‐Kava, Outcome 3 Sepcific side effects, Buspirone vs Kava‐Kava.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Ansseau 1990 {published data only}
    1. Ansseau, M, Papart, P, Gérard, MA, Von Frenckell, R, Franck, G. Controlled comparison of Buspirone and Oxazepam in Generalized Anxiety. Neuropsychobiology 1990‐91;24:74‐78. - PubMed
Boerner 2003 {published data only}
    1. *Boerner R, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. Kava‐Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder‐An 8‐week randomized, double‐blind multi‐cenre clinical trial in 129 out‐patients. Phytomedicine 2003;10(Supplement IV):38‐49. - PubMed
Bond 2002 {published data only}
    1. Bond AJ, Wingrove J, Curran HV, Lader MH. Treatment of generalised anxiety disorder with a short course of psychological therapy, combined with buspirone or placebo. Journal of Affective Disorders 2002;72:267‐271. - PubMed
Boral 1989 {published data only}
    1. Boral GC, Bandopadhaya G, Ike VG, Jha RJ, Navani SR, Bowalekar SK, Raghu CN. Double‐Blind, Randomized Clinical Evaluation of Buspirone and Diazepam in Generalized Anxiety Disorders. Advances In Therapy 1989;6(3):112‐124.
Borison 1990 {published data only}
    1. *Borison, RL, Albrecht, JW, Diamond, BI. Efficacy and safety of a putative anxyiolitic agent: Ipsapirone. Psychopharmacology Bulletin 1990;6(26):207‐209. - PubMed
Boyer 1993 {published data only}
    1. *Boyer, WF, Feighner, JP. A lacebo‐controlled double‐blind multicenter trial of two doses of ipsapirone versus diazepam in generalized anxiety disorder. International Clinical Psychopharmacology 1993;8:173‐176. - PubMed
Chiaie 1995 {published data only}
    1. Chiaie, RD, Pancheri, P, Casacchia, M, Stratta, P, Kotzalidis, GD, Zibellini, M. Assessment of the efficacy of Buspirone in patients affected by generalized anxiety disorder, shifting to Buspirone from prior treatment with Lorazepam: a placebo‐controlled, double blind study. Journal of Clinical Psychopharmacology 1995;15(1):12‐19. - PubMed
Cohn 1986 {published data only}
    1. *Cohn, JB, Wilcox, CS. Low‐sedation potential of Buspirone compared with Alprazolam and Lorazepam in the treatment of anxious patients: A double‐blind study. The Journal of Clinical Psychiatry 1986;47(8):409‐412. - PubMed
Cohn 1986a {published data only}
    1. Cohn J, Bowden C, Fisher J, Rodos J. Double‐blind comparison of buspirone and clorazepate in anxious outpatients. American Journal of Medicine 1986;80(3B):10‐16. - PubMed
Cohn 1989 {published data only}
    1. Cohn, J, Rickels, K. A pooled, double‐blind comparison of the effects of buspirone, diazepam and placebo in women with chronic anxiety. Current Medical Research and Opinion 1989;11(5):304‐320. - PubMed
Cutler 1993 {published data only}
    1. *Cutler, NR, Sramek, JJ, Wardle, TS, Hesselink, JMK, Roeschen, JK. The Safety and Efficacy of Ipsapirone vs. Lorazepam in outpatients with Gneralized Anxiety Disorder (GAD): Single Site Findings from a Multicenter Trial. Psychopharmacology Bulletin 1993;29(2):303‐308. - PubMed
Cutler 1994 {published data only}
    1. *Cutler, NR, Hesselinnk, JM, Sramek, JJ. A phase II multicenter dose‐finding, efficacy and safety trial of Ipsapirone in outpatients with generalized anxiety disorder. Progress in Neuro‐psychopharmacology & Biological Psychiatry 1994;18:447‐463. - PubMed
Davidson 1999 {published data only}
    1. *Davidson, JRT, DuPont, RL, Hedges, D, Haskins, JT. Efficacy, safety and tolerability of Venlafaxine Extended Release and Buspirone in outpatients with Generalized Anxiety Disorder. The Journal of Clinical Psychiatry 1999;60(8):528‐535. - PubMed
Demartinis 2000 {published data only}
    1. DeMartinis, N, Runn, M, Rickels, K, mandos, L. Prior Benzodiazepine Use and Buspirone Response in the Treatment of Generalized Anxiety Disorder. The Journal of Clinical Psychiatry 2000;61(2):91‐94. - PubMed
Enckelmann 1991 {published data only}
    1. Enkelmann, R. Alprazolam versus Buspirone in the treatment of outpatients with Genralized Anxiety Disorder. Psychopharmacology 1991;105:428‐432. - PubMed
Fabre 1987 {published data only}
    1. Fabre L. Double‐Blind Comparison of Buspirone with Diazepam in Anxious Patients. Current Therapeutic Research, Clinical & Experimental 1987;41(5):751‐758.
Feighner 1982 {published data only}
    1. Feighner, JP, Merideth, CH, Gordon AH. A Double‐Blind Comparison of Buspirone and Diazepam in Outpatients with Generalized Anxiety Disorder. The Journal of Clinical Psychiatry 1982;43(12 [sec 2]):103‐107. - PubMed
Feighner 1989 {published data only}
    1. Feighner, JP, Cohn, JB. Analysis off Individual Symptoms in Generalized Anxiety ‐ a Pooled, Multistudy, Double‐Blind Evaluation of Buspirone. Neuropsychobiology 1989;21:124‐130. - PubMed
Fontaine 1993 {published data only}
    1. Fontaine R, Napoliellow MJ. Double‐Blind Comparison of Buspirone 10 mg BID versus Buspirone 5mg TID in Generalized Anxiety Disorder. Current Therapeutic Research 1993;54(2):254‐261.
Fresquet 2000 {published data only}
    1. Fresquet, A, Sust, M, Lloret, A, Murphy, MF, Carter, FJ, Campbell, GM, Marion‐Landais, G. Efficacy and safety of Lesopitron in Outpatients with Generalized Anxiety Disorder. The Annals of Pharmacotherapy 2000;34:147‐153. - PubMed
Harto 1988 {published data only}
    1. Harto, NE, Roland, J, Branconnier, MA, Spera, KF, Dessain, EC. Clinical Profile of Gepirone, a Nonbenzodiazepine Anxiolytic. Psychopharmacology Bulletin 1988;24(1):154‐160. - PubMed
Jacobson 1985 {published data only}
    1. Jacobson, AF, Dominguez, RZ, Goldstein, BJ, Steinbook, RM. Comparison of Buspirone and Diazepam in Generalized Anxiety Disorder. Pharmacotherapy 1985;5(5):290‐296. - PubMed
Laakmann 1998 {published data only}
    1. *Laakmann, G, Schule, C, Lorkowski, G, Baghai, T. Buspirone and Lorazepam in the treatment of generalized anxiety disorder in outpatients. Psychopharmacology 1998;136:357‐366. - PubMed
Lader 1998 {published data only}
    1. *Lader, M, Scotto, JC. A multicentre double‐blind comparison of hydroxizine, buspirone and placebo in patients with GAD. Psychopharmacology 1998;139:402‐406. - PubMed
Lemone 1996 {published data only}
    1. Lemoine P, Rouillon F, Pouget D. Efficacy and withdrawal of clobazam, lorazepam and buspirone in the treatment of anxiety disorders [Efficacite et sevrage du clobazam comparativement au lorazepam et a la buspirone dans le traitement du trouble anxiete generalisee]. Encephale 1996;22(6):461‐7. - PubMed
Majercsik 2003 {published data only}
    1. Majercsik E, Haller J, Leveleki C, Baranyi J, Halasz J, Rodgers R. The effect of social factors on the axiolytic efficacy of buspirone in male rats, male mice, and men. Prgress in Neuro‐Psychopharmacology & Biological Psychiatry 2003;27:1187‐1199. - PubMed
Murphy 1989 {published data only}
    1. Murphy S, Owen R, Tyrer P. Comparative Assessment of Efficacy and Withdrawal symptoms After 6 ad 12 Weeks' Treatment with Diazepam or Buspirone. British Journal of Psychiatry 1989;154:529‐534. - PubMed
Pecknold 1985 {published data only}
    1. Pecknold, JC, Familamiri, P, Chang, H, Wilson, R, Alarcia, J, McClure, J. Buspirone: Anxiolytic?. Progress in Neuro‐psychopharmacology & Biological Psychiatry 1985;9:638‐642. - PubMed
Pecknold 1989 {published data only}
    1. Pecknold, JC, Matas, M, Howarth, BG, Ross, C, Swinson, R, Vezeau, C, Ungar, W. Evaluation of Buspirone as an antianxiety agent: Buspirona and Diazepam versus Placebo. Canadian Journal of Psychiatry 1989;34:766‐771. - PubMed
Pollack 1997 {published data only}
    1. Pollack, MH, Worthington, JJ, Manfro, GG, Otto, MW, Zucker, BG. Abecarnil for the Treatment of Generalized Anxiety Disorder: A Placebo‐Controlled Comparison of Two Dosage Ranges of Abecarnil and Buspirone. The Journal of Clinical Psychiatry 1997;58(suppl 11):19‐23. - PubMed
Ramchandran 1990 {published data only}
    1. Ramchandran, V, Thirunavukarasu, M, Oke, VG, Jha, J, Navani, SR, Bowalekar, SK, Raghu, SN. Comparative Clinical Evaluation of Buspirone and Diazepam in Generalized Anxiety Disorder. Current Therapeutic Research 1990;47(3):502‐510.
Rickels 1997 {published data only}
    1. *Rickels, K, Schweizer, E, DeMartinis, N, Mandos, L, Mercer, C. [Gepirone and Diazepam in Generalized Anxiety Disorder: A Placebo‐Controlled Trial]. Journal of Clinical Psychopharmacology 1997;17(4):272‐277. - PubMed
Ross 1987 {published data only}
    1. Ross, CA, Matas, M. A Clinical Trial of Buspirone and Diazepam in the Treatment of Generalized Anxiety Disorder. Canandian Journal of Psychiatry 1987;32:351‐355. - PubMed
Sacchetti 1994 {published data only}
    1. Sacchetti E, Zerbini O, Banfi F. Tansella M. Overlap of Buspirone with Lorazepam, Diazepam and Bromazepam in Patients with Generalized Anxiety Disorder: Findings from a Controlled, Multicentre, Double‐Blind Study. Human Psychopharmacology 1994;9:409‐422.
Sramek 1996a {published data only}
    1. Sramek JJ, Tansma M, Suri A, Hornig‐Rohan M, Amsterdam JD, Stahl SM, Weisler RH, Cutler NR. Efficacy of Buspirone in Generalized Anxiety Disorder with Coexisting Mild Depressive Symptoms. The Journal of Clinical Psychiatry 1996;57:287‐291. - PubMed
Sramek 1997 {published data only}
    1. Sramek JJ, Frackiewicz EJ, Cutler NR. Efficacy and Safety of Two Dosing Regimens of Buspirone in the Treatment of Outpatients with Persistent Anxiety. Clinical Therapeutics 1997;19(3):498‐506. - PubMed

References to studies excluded from this review

Bourin 1995 {published data only}
    1. Bourin M, Malinge M. Controlled comparison of the effects and abrupt discontinuation of buspirone and lorazepam. Progress in Neuro‐Psychopharmacology and Biological Psychiatry 1995;19:567‐575. - PubMed
Bouvard 1998 {unpublished data only}
    1. Bouvard M. Buspirone in Adolescents with Anxiety Disorders. American Psychiatric Association, Annual Meeting. 1998.
Caetano 1990 {published data only}
    1. Caetano D, Oliveira J. Double blind comparative study between bsupirone and lorazepam in the treatment of generalized anxiety. Jornal Brasileiro de Psiquiatria 1990;39(1):43‐46.
Costa e Silva 1987 {published data only}
    1. Costa e Silva J, Ruschel S. A double‐blind comparison between buspirone vs bromazepm in outpatients with symptoms of anxiety. Jornal Brasileiro de Psiquiatria 1987;36(4):253‐8.
Fontaine 1987 {published data only}
    1. Fontaine, R, Reaudry, P, Beauclair, L, Chouinard, G. Comparison of withdrawal of Buspirone and Diazepam: A placebo‐controlled study. Progress in Neuro‐Psychopharmacol & Biological Psychiatry 1987;11:189‐197. - PubMed
Goldberg 1982 {published data only}
    1. Goldberg, HL, Finnerty, R. Comparison of Buspirone in Two Separate Studies. The Journal of Clinical Psychaitry 1982;43(12[sec 2]):87‐92. - PubMed
Lucki 1987 {published data only}
    1. Lucki I, Rickels K, Giesecke M, Geller A. Differential effects of the anxiolytic drugs, diazepam and buspirone, on memory function. British Journal of Clinical Pharmacology 1987;23(2):207‐11. - PMC - PubMed
Olajide 1987 {published data only}
    1. Olajide, D, Lader, M. A Comparison of Buspirone, Diazepam and Placebo in Patients with Chronic Anxiety States. Journal of Clinical Psychopharmacology 1987;7(3):148‐152. - PubMed
Petracca 1990 {published data only}
    1. Petracca, A, Nisita, C, McNair, D, Melis, GB, Guerani, G, Cassano, GB. Treatment of Generalized Anxiety Disorder: Preliminary Clinical Experience With Buspirone. The Journal of Clinical Psychiatry 1990;51(9 [suppl]):31‐39. - PubMed
Rickels 1982 {published data only}
    1. Rickels K, Weisman K, Norstad N, Singer M, Stoltz D, Brown A, Danton J. Buspirone and diazepam in anxiety: a controlled study. Journal of Clinical Psychiatry 1982;43(12 Pt 2):81‐6. - PubMed
Rickels 1988 {published data only}
    1. Rickels K, Schweizer E, Csanalosi I, Case W, Chung H. Long‐term Treatment of Anxiety and Risk of Withdrawal. Archives of General Psychiatry 1988;45(5):444‐450. - PubMed
Rickels 2000 {published data only}
    1. Rickels, K, DeMartinis, N, Garcia‐España, F, Greeblatt, DJ, Mandos, LA, Rynn, M. Imipramine and Buspirone in Treatment of Patients With Generalized Anxiety Disorder Who are Discontinuing Long‐Term Benzodiazepine Therapy. The American Journal of Psychiatry 2000;157(12):1973‐1979. - PubMed
Rolland 2000 {published data only}
    1. Rolland P, Kablinger A, Brannon G, Freeman A. Treatment of Generalised Anxiety Disorder with Venlafaxine XR. Clinical Drug Investigation 2000;19(2):163‐165.
Rouillon 1995 {published data only}
    1. Rouillon F. A double‐blind controlled study of PCR 7060 vs buspirone in the treatment of generalised anxiety disorder. European Neuropsychopharmacology 1995;5(3):367.
Schweizer 1990 {published data only}
    1. Schweizer E, Rickels K, Csanalosi I, London J, Turner D. A Placebo‐Conrolled Study of Enciprazine in the Treatment of Generalized Anxiety Disorder: A Preliminary Report. Psychopharmacology Bulletin 1990;26(2):215‐217. - PubMed
Shah 1991 {published data only}
    1. Shah, AV, Parulkar, GB, Mattoo, V, Bowalekar, SK, Raghu, CN. Clinical evaluation of Buspirone and Diazepam in Generalized Anxiety Disorders. Current Therapeutic Research 1991;50(6):827‐834.
Shen 1999 {published data only}
    1. Shen J, Zhong X. Clinical study on buspirone hydrochloride treated for generalized anxiety disorder. Journal of Chinese Civil Administration Medicine 1999;11(2):70‐2.
Sontheimer 2001 {published data only}
    1. Sontheimer DL, Ables AZ. Is Imipramine or Buspirone Treatment Effective in Patients Wishing to Discontinue Long‐Term Benzodiazepine Use?. Family Practice 2001;50(3):203. - PubMed
Sramek 1996 {published data only}
    1. *Sramek, JJ, Fresquet A, Gaston M‐L, Hourani J, Jhee SS, Martinez L, Jensen C, Bolles K, Carrington A, Cutler N. Establishing the Maximum Tolerated Dose of Lesopitron in Patients With Generalized Anxiety Disorder: A Bridging Study. Journal of Clinical Psychopharmacology 1996;16(6):454‐458. - PubMed
Strand 1990 {published data only}
    1. Strand, M, Hetta, J, Rosen, A, Sorensen, S, Malmstrom, R, Fabian, C, Marits, K, Vetterskog, K, Liljestrand, AG, Hegen, C. A Double‐Blind Controlled Trial in Primary Care Patients With Generalized Anxiety: A Comparison Between Buspirone and Oxazepam. The Journal of Clinical Psychiatry 1990;51(9 [suppl]):40‐45. - PubMed
Tollefson 1991 {published data only}
    1. *Tollefson, GD, Lancaster, SP, Montague‐Clouse, J. The Association of Buspirone ands Its Metabolite 1‐pyrimidinylpiperazine in the Remission of Comorbid Anxiety with Depressive Features and Alcohol Dependency. Psychopharmacology Bulletin 1991;27(2):163‐170. - PubMed
Tyrer 1984 {published data only}
    1. Tyrer P, Owen R. Anxiety in primary care: is short‐term drug treatment appropriate?. Journal of Psychiatric Research 1984;18(1):73‐8. - PubMed
van Amerongen 1991 {published data only}
    1. Amerongen A, Viel J, Konopka C, Berdeaux G. French multicenter dose‐ranging trial of ipsapirone in GAD patients: a randomized, double‐blind parallel group placebo‐controlled trial. 5th World Congress of Biological Psychiatry. Florence, 9‐14 June, 1991.
van Laar 1992 {published data only}
    1. Laar M, Volkerts E, Willigenburg A. Therapeutic efects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. Journal of Clinical Psychopharmacology 1992;12(2):86‐95. - PubMed
Wheatley 1982 {published data only}
    1. Wheatley, D. Buspirone: Multicenter Efficacy Study. The Journal of Clinical Psychiatry 1982;43(12[sec 2]):92‐94. - PubMed
Yevich 1990 {published data only}
    1. Yevich JP, Eison MD, Eison AS, Taylor DP, Yocca FD, VanderMaelen CP, Riblet LA, Robinson DS, Roberts Dl, Temple DL. Gepirone hydrochloride: preclinical pharmacology and recent clinical findings. Current and Future Trends in Anticonvulsant, Anxiety, and Stroke Therapy 1990;361:443‐51. - PubMed

Additional references

Altman 1996
    1. Altman DG, Bland JM. Detecting skeweness fromsummary information. British Medical Journal 1996;313(7066):1200. - PMC - PubMed
Ballenger 2001
    1. Ballenger, JC, Davidson, JRT, Lecrubier, Y, Nutt, DJ, Borkovec, T, Rickels K, Stein, D, Wittchen, H. Consensus statement on Generalized Anxiety Disorder from the Tenth Internation Consensus Group on Depression and Anxiety. The Journal of Clinical Psychiatry 2001;62(suppl 11):53‐58. - PubMed
Borkovec 1993
    1. Borkovec TD, Costello E. Efficacy of applied relaxation and cognitive behavioral therapy in the treatment of generalized anxiety disorder. Journal Consulting and Clinical psychology 1993;61:611‐19. - PubMed
Brawman‐Mintzer 2001
    1. Brawman‐Mintzer O. Pharmacological treatment of Generalized Anxiety Disorder. The Psychiatric Clinics of North America 2001;24(1):119‐137. - PubMed
Bruce 2005
    1. Bruce SE, Yonker KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, Shea MT, Keler MB. Influence of Psychiatric Comorbidity on Recovery and Recurrence in Generalized Anxiety Disorder, Social Phobia, and Panic Disorder: A 12‐Year Prospective Study. American Journal of Psychiatry 2005;162:1179‐1187. - PMC - PubMed
Gammans 1992
    1. Gammans RE, Stringfellow JC, Hvizdos AJ, Seidehamel RJ, Cohn JB, Wilcox CS, Fabre LF, Pecknold Jc, Smith Wt, Rickels K. Use of buspirone in patients with generalized anxiety disorde and coexising depressive symtoms. A meta‐analysis of eight randomized, controlled studies. Neuropsychobiology 1992;24(4):193‐201. - PubMed
Goa 1986
    1. Goa KL, Ward A 32. Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.. Drugs (New Zealand) 1986;2:114‐129. - PubMed
Hamilton 1959
    1. Hamilton, M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50‐55. - PubMed
Higgins 2005
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Intrventions 4.2.4 [updated March 2005]. In: The Cochrane Library, Issue 2, 2005. Chichester, UK: John Wiley & Sons, Ltd..
Kapczinski 2005
    1. Kapczinski F, Lima MS, Souza S, Cunha A, Schmitt R. Antidepressants for generalized anxiety disorder (Review). The Cochrane Collaboration 2005. - PubMed
Kessler 1994
    1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H‐U, Kendler KS. Lifetime and 12‐month prevalence of DSM‐III‐R psychiatric disorers in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry 1994;51:8‐19. - PubMed
Lydiard 1997
    1. Lydiard, RB, Ballenger, JC, Rickels, K. A Double‐Blind Evaluation of the Safety and Efficacy of Abecarnil, Alprazolam and Placebo in Outopatients with Generalized Anxiety Disorder. The Journal of Clinical Psychiatry 1997;58(suppl 11):11‐18. - PubMed
Mandos 1995
    1. Mandos LA, Rickels K, Cutler N, Roeschen J, Keppel Hesselink JM, Schweizer E. Placebo‐controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder. International Clinical Psychopharmacology 1995;10:251‐256. - PubMed
Meoni 2001
    1. Meoni P: Salina E, Yves B, Hackett D. Pattern of Symptom Improvement Following Treatment with Venlafaxine XR in Patients with Generalized Anxiety Disorder. The Journal of Clinical Psychiatry 2001;62(11):888‐893. - PubMed
Pittler 2001
    1. Pittler MH, Ernst E. Kava extract for treating anxiety (Cochrane Review). Cochrane Database Systematic Review 2001, Issue 4. [CD003383] - PubMed
Shader 1993
    1. Shader, RI, Greenblatt, DJ. Use of benzodiazepines in anxiety disorders. New England Journal of Medicine 1993;328:1398‐1405. - PubMed
Wingerson 1992
    1. Wingerson D, Nguyen C, Roy‐Byrne PP. Chlomipramine treatment for Generalized Anxiety Disorder [Journal of Clinical Psychopharmacology]. 1992; Vol. 12, issue 3:214‐215. - PubMed
Wittchen 1994
    1. Wittchen, HU, Zhao, S, Kessler, RC, Eaton, WW. DSM III‐R generalized anxiety disorder in the national comorbidity survey. Archives of General Psychiatry 1994;51:355‐364. - PubMed

MeSH terms